Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two ...

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

There are now more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

Hello, Health Rounds Readers! Today we feature a study that found yet another potential health benefit of GLP-1 drugs, this ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.